196 related articles for article (PubMed ID: 30566038)
1. Predicting Patient Response to the Antiarrhythmic Mexiletine Based on Genetic Variation.
Zhu W; Mazzanti A; Voelker TL; Hou P; Moreno JD; Angsutararux P; Naegle KM; Priori SG; Silva JR
Circ Res; 2019 Feb; 124(4):539-552. PubMed ID: 30566038
[TBL] [Abstract][Full Text] [Related]
2. A distinct molecular mechanism by which phenytoin rescues a novel long QT 3 variant.
Gando I; Campana C; Tan RB; Cecchin F; Sobie EA; Coetzee WA
J Mol Cell Cardiol; 2020 Jul; 144():1-11. PubMed ID: 32339567
[TBL] [Abstract][Full Text] [Related]
3. Mexiletine rescues a mixed biophysical phenotype of the cardiac sodium channel arising from the SCN5A mutation, N406K, found in LQT3 patients.
Hu RM; Tester DJ; Li R; Sun T; Peterson BZ; Ackerman MJ; Makielski JC; Tan BH
Channels (Austin); 2018; 12(1):176-186. PubMed ID: 29983085
[TBL] [Abstract][Full Text] [Related]
4. Complex interactions in a novel SCN5A compound mutation associated with long QT and Brugada syndrome: Implications for Na+ channel blocking pharmacotherapy for de novo conduction disease.
Liu J; Bayer JD; Aschar-Sobbi R; Wauchop M; Spears D; Gollob M; Vigmond EJ; Tsushima R; Backx PH; Chauhan VS
PLoS One; 2018; 13(5):e0197273. PubMed ID: 29791480
[TBL] [Abstract][Full Text] [Related]
5. Functional characterization and identification of a therapeutic for a novel SCN5A-F1760C variant causing type 3 long QT syndrome refractory to all guideline-directed therapies.
Stutzman MJ; Gao X; Kim M; Ye D; Zhou W; Tester DJ; Giudicessi JR; Shannon K; Ackerman MJ
Heart Rhythm; 2023 May; 20(5):709-717. PubMed ID: 36731785
[TBL] [Abstract][Full Text] [Related]
6. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients.
Ruan Y; Liu N; Bloise R; Napolitano C; Priori SG
Circulation; 2007 Sep; 116(10):1137-44. PubMed ID: 17698727
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a novel LQT3 variant with a selective efficacy of mexiletine treatment.
Kim HJ; Kim BG; Park JE; Ki CS; Huh J; Youm JB; Kang JS; Cho H
Sci Rep; 2019 Sep; 9(1):12997. PubMed ID: 31506521
[TBL] [Abstract][Full Text] [Related]
8. Trafficking defects and gating abnormalities of a novel SCN5A mutation question gene-specific therapy in long QT syndrome type 3.
Ruan Y; Denegri M; Liu N; Bachetti T; Seregni M; Morotti S; Severi S; Napolitano C; Priori SG
Circ Res; 2010 Apr; 106(8):1374-83. PubMed ID: 20339117
[TBL] [Abstract][Full Text] [Related]
9. Molecular biology of the long QT syndrome: impact on management.
Priori SG; Napolitano C; Paganini V; Cantù F; Schwartz PJ
Pacing Clin Electrophysiol; 1997 Aug; 20(8 Pt 2):2052-7. PubMed ID: 9272507
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Gating Properties and Use-Dependent Block of Nav1.5 and Nav1.7 Channels by Anti-Arrhythmics Mexiletine and Lidocaine.
Wang Y; Mi J; Lu K; Lu Y; Wang K
PLoS One; 2015; 10(6):e0128653. PubMed ID: 26068619
[TBL] [Abstract][Full Text] [Related]
11. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy.
Schwartz PJ; Priori SG; Locati EH; Napolitano C; Cantù F; Towbin JA; Keating MT; Hammoude H; Brown AM; Chen LS; Colatsky TJ
Circulation; 1995 Dec; 92(12):3381-6. PubMed ID: 8521555
[TBL] [Abstract][Full Text] [Related]
12. Malignant perinatal variant of long-QT syndrome caused by a profoundly dysfunctional cardiac sodium channel.
Wang DW; Crotti L; Shimizu W; Pedrazzini M; Cantu F; De Filippo P; Kishiki K; Miyazaki A; Ikeda T; Schwartz PJ; George AL
Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):370-8. PubMed ID: 19808432
[TBL] [Abstract][Full Text] [Related]
13. A novel SCN5A arrhythmia mutation, M1766L, with expression defect rescued by mexiletine.
Valdivia CR; Ackerman MJ; Tester DJ; Wada T; McCormack J; Ye B; Makielski JC
Cardiovasc Res; 2002 Aug; 55(2):279-89. PubMed ID: 12123767
[TBL] [Abstract][Full Text] [Related]
14. A revised view of cardiac sodium channel "blockade" in the long-QT syndrome.
Kambouris NG; Nuss HB; Johns DC; Marbán E; Tomaselli GF; Balser JR
J Clin Invest; 2000 Apr; 105(8):1133-40. PubMed ID: 10772658
[TBL] [Abstract][Full Text] [Related]
15. Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation.
Windle JR; Geletka RC; Moss AJ; Zareba W; Atkins DL
Ann Noninvasive Electrocardiol; 2001 Apr; 6(2):153-8. PubMed ID: 11333173
[TBL] [Abstract][Full Text] [Related]
16. Effects of sodium channel block with mexiletine to reverse action potential prolongation in in vitro models of the long term QT syndrome.
Sicouri S; Antzelevitch D; Heilmann C; Antzelevitch C
J Cardiovasc Electrophysiol; 1997 Nov; 8(11):1280-90. PubMed ID: 9395171
[TBL] [Abstract][Full Text] [Related]
17. Lidocaine attenuation testing: An in vivo investigation of putative LQT3-associated variants in the SCN5A-encoded sodium channel.
Anderson HN; Bos JM; Kapplinger JD; Meskill JM; Ye D; Ackerman MJ
Heart Rhythm; 2017 Aug; 14(8):1173-1179. PubMed ID: 28412158
[TBL] [Abstract][Full Text] [Related]
18. Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells.
Ma D; Wei H; Zhao Y; Lu J; Li G; Sahib NB; Tan TH; Wong KY; Shim W; Wong P; Cook SA; Liew R
Int J Cardiol; 2013 Oct; 168(6):5277-86. PubMed ID: 23998552
[TBL] [Abstract][Full Text] [Related]
19. Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes.
Viswanathan PC; Bezzina CR; George AL; Roden DM; Wilde AA; Balser JR
Circulation; 2001 Sep; 104(10):1200-5. PubMed ID: 11535580
[TBL] [Abstract][Full Text] [Related]
20. Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics.
Terrenoire C; Wang K; Tung KW; Chung WK; Pass RH; Lu JT; Jean JC; Omari A; Sampson KJ; Kotton DN; Keller G; Kass RS
J Gen Physiol; 2013 Jan; 141(1):61-72. PubMed ID: 23277474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
